I Stopped My GLP-1 and I'm Thinking About Restarting — Here's the Data

The pen has been in my refrigerator door for eight months.

I stopped semaglutide last fall — Wegovy, in my case. Not because I decided to, exactly, but because my coverage lapsed and the math stopped working. For a while I told myself I'd take a short break and pick it back up. Then the break became a season, the season became eight months, and the weight I'd worked off started, quietly, to come back. Somewhere in there a specific worry moved in and wouldn't leave: was I the only one who couldn't make it stick?

So I went looking for the numbers, the real ones, not the testimonials. What I found changed how I read the whole thing, and this is me walking through it for anyone sitting where I was.

Stopping isn't the exception. It's the norm.

Here's the fact that moved me out of my own head.

In a US real-world study that followed adults newly starting a GLP-1 medication — built from insurance claims and medical records, not a tidy controlled trial — 53.6% had stopped within the first year. By the two-year mark, 72.2% had. More than half gone inside twelve months. Nearly three-quarters within two years.

I read that twice. Stopping a GLP-1 isn't some rare stumble. Statistically it's the common path, the thing most people do, not the thing that marks you out.

That single number didn't fix anything on its own. But it moved me from "what is wrong with me" to "this is a known pattern, so what does the pattern say to do next?" And the answer to that has a few parts.

I'd been carrying my stop like a private failing. The data reads it as a footnote: the majority experience, not the exception. That shift in framing did more for me than any pep talk.

Why so many stop — and why the weight-only crowd stops most

The same study split people by whether they had type 2 diabetes, and the gap was hard to miss.

Among people on a GLP-1 who also had type 2 diabetes, 46.5% stopped within a year. Among people taking it for weight alone, no diabetes, 64.8% did. If you're in that second group, as I was, you're in the group that walks away more often. That's not a character flaw showing up in a spreadsheet. It's a pattern with reasons, and the reasons rhyme with mine.

The study counted who stopped, not why. So I'm not going to hand you a tidy pie chart of causes and pretend the data drew it. What I can tell you is what comes up again and again when people describe it in their own words:

• Cost and coverage. Mine lapsed. Prior authorizations expire, plans drop the drug from the formulary, the cash price is steep, well over a thousand dollars a month at US list price before any help. What people actually pay swings widely, though — it depends on your plan, your dose, and any manufacturer savings program — so list price and out-of-pocket cost aren't the same number. This is the one I hear most from people who used it for weight.
• Side effects. The gut stuff is real, and for some people it never settles enough to feel worth it.
• Reaching a goal. Some people hit a number they wanted and figure they'll coast from there.
• Access and supply. Shortages, a pharmacy that can't fill it, a prescriber who moves on.

None of those is "failure." They're the ordinary friction of staying on a long-term medication inside a system that doesn't make it easy. The weight-only group is the one I hear that friction from most — cost above all — though the study can't tell us how much of the 64.8% any one reason accounts for.

The weight comes back when you stop. That isn't the same as failing.

This is the part people are most afraid to look at, so let's look at it head-on.

When you stop, the weight tends to return. Not always all of it, not always fast, but the direction is real and it has been measured. The clearest picture comes from an extension of the STEP 1 trial, which tracked people after they came off semaglutide 2.4 mg.

By week 120 — about a year after the drug was withdrawn — the semaglutide group had regained 11.6 percentage points of body weight, against 1.9 for the placebo group. And yet even after that rebound, they were still ahead of where they'd started, with a net loss of 5.6% from baseline versus 0.1% for placebo.

Let me be careful with that 11.6, because it's easy to misread. It's the portion that came back: 11.6% of their starting weight, roughly two-thirds of everything they had lost. Set that beside the portion that stayed off, a net 5.6% still below baseline. Most of the loss returned; a real piece of it held.

The researchers didn't frame this as a group of people failing. They framed it as evidence that obesity behaves like a chronic condition, one that pushes back the moment you stop treating it, the same way blood pressure drifts up when someone stops their blood-pressure pill.

Nobody says a person "failed" their statin because their cholesterol climbed after they quit taking it. The medicine was doing a job; the job ended when the medicine did. Weight works the same way, and the biology isn't a verdict on your discipline.

That was the thing I most needed to hear eight months ago. The regain on my own scale wasn't proof I was weak. It was proof the drug had been doing something real, and that the something stops when the drug does.

Plenty of people start again, too

If stopping is common, so is coming back, and that surprised me more than any other figure in the study.

Among people who had stopped, a large share later restarted a GLP-1. For people with type 2 diabetes, 47.3% picked it back up. For people without diabetes, 36.3% did.

The second row is the one that's mine. Almost two out of three people in the weight-only group stopped, and then more than a third of them came back. For a lot of people, "I quit" turned out not to be the final answer. It was a pause. Sometimes a long one, like mine.

That's the quiet correction the data made to my own story. I'd been treating my eight-month gap as a verdict, proof the whole thing hadn't worked and never would. The numbers say something gentler: a gap is a common chapter, not the ending.

Restarting doesn't mean jumping back to your old dose

This is the practical question that sent me down the rabbit hole in the first place. If I go back, do I start where I left off, or somewhere lower?

The label answers it, and the answer is lower. Semaglutide's prescribing information — the Wegovy label, here in the US — says that if 2 or more consecutive weekly doses are missed, you restart the dose escalation at a lower dose, deliberately climbing back up the ladder to reduce the risk of gastrointestinal side effects. Your gut loses its tolerance during a gap. Dropping straight back onto your old maintenance dose is how people end up flattened by nausea.

One thing I want to be precise about, because it matters. That instruction is written to the person prescribing the drug, not to you and your bathroom cabinet. It's guidance for building a re-titration plan with a clinician, not a green light to freelance your way back on leftover pens. After an eight-month gap, "where do I restart" is a medical question with a real answer, and that answer comes from someone who can see your whole history: not a forum thread, and not me.

The re-titration exists for the same reason the slow ramp existed the first time: your body gets a vote. Skipping the climb doesn't get you there faster. It usually just makes the first weeks miserable enough that you quit all over again.

So the real shape of a restart isn't "resume." It's "start low, climb again, with a plan." Slower on paper. Kinder in practice.

What tends to be different the second time around

Nobody can promise you a smoother ride the second time. The trials didn't measure "round two," and I'm not going to invent a statistic to make you feel better. But a few things genuinely are different once you've done this before, and they're worth naming.

You know the drill now. The first time, everything was new and slightly frightening: the click of the pen, the timing, the wondering whether that twinge was normal. The second time, the mechanics are muscle memory, which frees up a surprising amount of mental space.

You know your own side-effect pattern. If nausea hit hardest in the first few days last time, you can plan the calendar around it instead of getting ambushed. You know which foods your stomach turned on. That's hard-won information you simply didn't have on day one the first time.

And your expectations are calibrated. You already learned, the expensive way, that the scale moves in fits and starts, that a stall isn't a stop, and that the headline numbers are averages hiding a wide spread. Walking in without the fantasy of a straight line down is, honestly, a healthier place to start from.

What stays the same: the boring fundamentals still do the heavy lifting. Protein you genuinely eat. Movement you'll genuinely keep doing. Sleep. The drug quiets appetite; it was never going to lift the weights for you. None of that changes on the second attempt, but the second time, you already believe it, because you lived the first.

The lines worth checking before you go back

Before a restart there's a tier of safety questions, and they don't all carry the same weight. Lumping them together is how people either panic over the wrong thing or wave off the thing that genuinely matters. So here they are, in order of severity.

At the top is a hard stop. In the US, the semaglutide label carries a boxed warning — the FDA's most serious kind — tied to thyroid C-cell tumors. It's a flat contraindication for anyone with a personal or family history of medullary thyroid carcinoma, or the condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is not a "weigh the pros and cons" item. If that history applies to you, it rules restarting out, full stop, and it's the same answer whether it's your very first dose or your fifth restart.

One grade down sits a warning, not a ban. Acute pancreatitis has been reported in people on GLP-1 medicines. The label doesn't bar treatment over it up front; it tells clinicians to stop the drug if pancreatitis is suspected. In practice that means severe, persistent stomach pain is a same-day call to your doctor, not something to ride out. A caution to act on, not a locked door.

Then there's the everyday tier: nausea, vomiting, and diarrhea, the gastrointestinal reactions most people associate with these drugs. These aren't rare, and they aren't a reason not to restart. They're the expected, usually-manageable background noise, and they're the whole reason the dose climbs back slowly instead of all at once.

One caveat on all of it: "boxed warning" is US FDA language. If you're reading from outside the US, your own regulator's approvals, indications, and exact wording may differ. The tiers of seriousness travel well; the specifics are worth checking against your country's label and your own prescriber.

What I'm bringing to the appointment

I booked the visit before I finished writing this, which tells you where I landed. Here's what I'm walking in with, less a script than a short list of things that make the conversation useful instead of vague.

Why I stopped, and the real reason. In my case, coverage. That's not a side detail; it's the actual problem to solve, and if I don't name it we'll build a plan that falls apart the same way the first one did. If cost or a denied prior authorization is your real obstacle, that belongs on the table, not tucked away out of embarrassment.

How long the gap has been. Eight months, for me. The length of the break shapes the re-titration plan: a two-week lapse and an eight-month one are not the same restart, and the label's own logic about missed doses is built around exactly that distinction.

What's left in the fridge, and whether it's still good. I have pens. I'm not going to guess about whether or how to use them; that's precisely the judgment I want a clinician making, given the gap and the storage. Bringing them to the visit beats improvising at home.

The plan for staying on, not just getting back on. The data's whole message is that this is a long-game condition. So the question worth asking isn't only "how do I restart." It's "what makes it likelier I stay on this time," whether that's a coverage fix, a slower ramp, or a check-in schedule that catches trouble before it becomes another eight-month gap.

The thing I wish I'd understood the first time: the appointment isn't a test of willpower and it isn't a confession. It's a planning meeting for a chronic condition. You bring the facts — the why, the how-long, the what's-left, the what-next — and you build the next chapter together.

Every number here comes from published clinical trials, a real-world cohort study, and the approved drug label. None of it decides anything for you: the call about restarting, and at what dose, belongs to you and a doctor who knows your history, not to a statistic and not to an essay. But if you've been sitting with a pen in the fridge door, wondering whether the gap means the story is over, the data's answer is about as clear as data gets. For a lot of people, it wasn't. Bring that to your next visit, and start there.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app